Zika Virus: Donor Screening and Handling CT Products in the Face of Emerging Viruses eCast (AABB Center for Cellular Therapies), September 21, 2017-September 21, 2019
Description: Live and On-Demand eCast. Newly emerging viruses, such as Zika virus, are a threat to the blood supply as well as autologous and allogenic cellular therapy products collected for use in transplants. Understanding the risk of Zika virus transmission, current donor testing and screening, and the regulations which help to prevent transmission are critical for patients undergoing cellular therapeutic procedures. The presenters will discuss current strategies used in collection facilities and stem cell laboratories to help mitigate the Zika virus outbreak.
Human Platelet Lysate Use in the Production of Cellular Therapies: Current State of the Art and Challenges to be Resolved On-Demand eCast (AABB Center for Cellular Therapies), August 4, 2016-August 4, 2018
Description: Participants from the Joint AABB-ISCT Working Group on Human Platelet Lysates discussed the current status and challenges of the production, standardization, pathogen reduction and quality control of HPL. Three experts in the field presented key areas of development that are critical to clinical translation of HPL. Three main topics were presented: Human platelet lysate (HPL) is being used as a substitute for FBS as a media supplement for manufacture of Advanced Therapies Medicinal Products; HPL is a potent media supplement for the manufacture of cell therapies; and HPL versus FBS for Human cell preparations: Most clinical trials have been performed with MSC isolated and expanded in fetal bovine serum (FBS).
Perinatal Cells and the Landscape of Ancillary Cord Blood Banking Services On-Demand eCast (AABB Center for Cellular Therapies), May 12, 2016-May 12, 2018
Description: Stem cells from perinatal tissues contain untapped life potential to treat many disorders. Sources of perinatal stem cells include umbilical cord blood, the Wharton’s Jelly of the umbilical cord, amniotic fluid, the amnion lining the amniotic cavity, the placenta itself- including chorionic mesenchymal stromal cells and multi-potent cells derived from the human term placenta and the endothelial progenitor cells collected from the umbilical cord vein. Knowledge of this source of stem cells will lead to better understanding of cells that may improve clinical outcomes. This program discussed the Landscape of Ancillary Cord Blood Banking Services with the primary focus on cord tissue derived product offerings. Representatives of the two largest cord blood banks in the United States, Viacord and Cord Blood Registry, shared information about the products that these much respected cord blood banks offer. The Chief Scientific Officer from Auxocell Laboratories, Inc. shared information about a new cord tissue processing that is available on the market and being adopted by many cord blood banks both internationally and domestically.
Impact of Cord Thaw Method on Processing and Clinical Outcome (ISCT)
Description: These free slides from the 2014 ISCT Annual Meeting compare different cord blood unit thaw methods and how they impact patient safety.
HLA Education Series (NMDP/Be The Match)
Description: These online education modules discuss several aspects of HLA, including: 1) how HLA matching is used to optimize patient outcomes and examine bidirectional, unidirectional, and graft rejection in transplant; 2) research used to determine the NMDP matching guidelines for unrelated donors and cord blood units; and, 3) HLA naming systems (serology and DNA), allele codes, and the three resolution levels of HLA typing. Account with NMDP/Be The Match learning management system required.
BMT Curriculum (NMDB/Be The Match)
Description: To give you exposure to the exciting biology and clinical practice of blood and marrow transplant, (BMT) leading transplant physicians have come together to develop 16 didactic curriculum modules and several testimonial videos on "why I chose BMT". These modules provide the fascinating history and future of BMT, fundamentals of the science behind transplant, state-of-the-field disease summaries, immunobiology and donor selection, early and late effects and more. One module describes how to mold a career in BMT. These modules can be used for the didactic portion of a BMT elective rotation for medical students and fellows. Other clinicians in hematology/oncology may also find them helpful.
Protecting Patients from Harm: Ethical, Legal & Policy Responses to Domestic and International Marketing of Clinically Unproven Stem Cell Interventions (PACT)
Description: This free webinar recording discusses the myth and reality of stem cells and regenerative medicine and the need for protecting patients from harm in the context of recent responses to marketing of unapproved stem cell-based interventions.
Software for Cellular Therapy Facilities: Homemade versus Commercial and why Facilities chose what they did (ISCT), April 2011
Description: This webinar discusses what type of software different cellular therapy facilities use and the pros and cons of the software choice.
Protecting Patients from Harm: Ethical, Legal & Policy Responses to Domestic and International Marketing of Clinically Unproven Stem Cell Interventions (PACT)
Description: This free webinar recording discusses the myth and reality of stem cells and regenerative medicine and the need for protecting patients from harm in the context of recent responses to marketing of unapproved stem cell-based interventions.
HLA Matching Guidelines for Selecting Unrelated Donors and CBUs for HCT (NMDP/Be The Match)
Description: Learn practical applications of the recently updated matching criteria for selection of marrow, PBSC, and cord blood unit (CBU) cell sources. Participants will gain perspective on which pre- and post-transplant factors have the most impact on outcomes, optimal match criteria for selecting marrow, PBSC, and CBUs, and the non-HLA factors that affect cell source decisions. Participants will also learn about ongoing research trials and impact on donor and cord selections and timing.
HLA Education Series (NMDP/Be The Match)
Description: These online education modules discuss several aspects of HLA, including: 1) how HLA matching is used to optimize patient outcomes and examine bidirectional, unidirectional, and graft rejection in transplant; 2) research used to determine the NMDP matching guidelines for unrelated donors and cord blood units; and, 3) HLA naming systems (serology and DNA), allele codes, and the three resolution levels of HLA typing. Account with NMDP/Be The Match learning management system required.
Immunogenetics Basic Science Symposium (ASHI), September 26, 2016
Description: This symposium will feature the immunogenetics of HLA and KIR genes. HLA class I and II genes are the most polymorphic genes in the human genome. HLA genes associate with an unprecedented range and number of human diseases, and contribute to the outcome of therapeutic intervention, most notably the transplantation of cells, tissues and organs. Physiological interactions of HLA class I and II, with families of variable lymphocyte receptors, diversify the human immune response to infection and cancer and, in the case of natural killer cells, implantation of embryos at the beginning of pregnancy.
42nd ASHI Annual Meeting (ASHI), September 26 - September 30, 2016
Description: The 42nd ASHI Annual Meeting will provide updates on basic Immunogenetics and on practice guidelines in clinical histocompatibility and immunogenetics.
CAP Annual Scientific Meeting (Pathologists' Meeting) September 25-28, 2016
Description:
Next-Generation Sequencing (NGS) Workshop (ASHI), November 10-11, 2016
Description: This special focus meeting is designed to provide education and facilitate networking for laboratories that want to learn more about NGS technology, are considering whether or not to pursue NGS-based typing, or are in the process of validating/implementing NGS-based HLA typing methods. The program will include a review of fundamental aspects of NGS-based methods, guidance for selecting an approach, description of challenges that can be encountered, criteria for validation, and suggestions for integrating NGS-based methods into routine laboratory operation. Representatives from small to large labs will describe their experience with NGS and be available for networking. Vendors will provide their perspectives through exhibits that will be available throughout the meeting and a luncheon session featuring sequential vendor presentations.
The Nuts and Bolts of Tests Implementation & ASHI Laboratory Accreditation (ASHI), October 12, 2016
Description: Medhat Askar, MD, PhD, MSHPE, FRCPath, Director, Transplant Immunology at Baylor University Medical Center, will give an overview of the nuts and bolts of tests implementation and ASHI laboratory accreditation.
Emergency Preparedness – From Hurricanes to Hetastarch (ISCT) March 2016
Description: This webinar will begin with a presentation reviewing the FACT-JACIE emergency preparedness and disaster planning requirements for all facilities and components of a transplant program. Examples of compliance with those standards will be provided as well as discussion the seminal paper (Wingard, 2006) that outlines a framework for disaster plans. Presentations will also address emergency preparedness from the processing facilities perspective and response to critical reagent shortages. In addition, this webinar will discuss operational threat assessment and development of a Continuity of Operations (COO) plan as a result of the Joplin (Nebraska) Medical Center tornado. Experiences will be shared concerning the process undertaken in implementing a laboratory-wide COO, with specific focus on the Biologics Processing Facility.
Promoting quality patient care and
laboratory practice in cellular therapies
Principal
Members:
© 2024 The Foundation for the Accreditation of Cellular Therapy.
All Rights Reserved.
